© Copyright 2015 Galapagos NV Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG1837 in healthy volunteers F.P. Vanhoutte 1, M-H.

Slides:



Advertisements
Similar presentations
Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study Garcia-Manero G et al. Proc ASH 2010;Abstract 603.
Advertisements

The Drug Discovery Process
Design of Bioequivalence Studies Alfredo García – Arieta, PhD
Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.
Scott Butler Infection Innovative Medicines Group AstraZeneca R&D, Boston CPTR Workshop, 2012 Arlington, VA AZD5847 Oxazolidinone for the treatment of.
Pilot and Pharmacokinetic Studies of Solubilized Estradiol Administered Vaginally in a Softgel Capsule James H. Pickar, M.D., F.A.C.O.G.
Charlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA
QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: Fax:
Overview of the Clinical Development EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use. ASENT 12 th Annual.
Pharmacokinetics as a Tool
Pipeline Session: NBI Human Pharmacokinetics of NBI-98854: A Selective Inhibitor of VMAT2 with an Attractive PK and Safety Profile for Hyperkinetic.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Recommendations on integrated safety summaries from Phase 1 studies
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Stages of drug development
Clinical Trials Amir Zarrinhaghighi
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Pharmaceutical chemistry Hit to lead. Chemistry in R&D Exploratory development Full development IDEAIDEA DrugDrug CANDIDATE POCTARGET Therapeutic research.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Regulatory requirements Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
RESEARCH Lymphatic Targeting of Tenofovir; Intracellular Pharmacokinetics and Viral Dynamics Arnold Fridland, Ph.D, William Lee, Ph.D. Gilead Sciences,
Clinical Aspects of Treatment with Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.
Overview of Phase 1 and 2a Safety and Efficacy Data of Maraviroc (UK-427,857) Mary McHale, Sam Abel, Deborah Russell, James Gallagher, Elna van der Ryst.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Artemisinin-based Products Dr. Henrike Potthast
INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.
© Copyright 2015 Galapagos NV Poster available online at: Defects in CFTR that result in Cystic Fibrosis can be broadly categorized into three.
Brett-Smith, ATAC, 2/24/02 Stavudine Extended Release (Zerit ® XR; d4T XR) Stavudine Prolonged Release Capsules ATAC Meeting 2/24/02.
GS-9350: A Pharmacoenhancer Without anti-HIV Activity AA Mathias, P German, M Lee, C Callebaut, L Xu, L Tsai, B Murray, H Liu, K Yale, D Warren and BP.
Reesink H, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/28/09.
PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.
P1586 THE FIRST JAK1-SELECTIVE INHIBITOR, FILGOTINIB, DISPLAYS SIMILAR MOLECULAR ACTIVITY IN THE GUT OF MICE WITH DSS-INDUCED COLITIS AND IN CULTURES OF.
Using additivity and bliss analysis to categorize corrector-corrector interactions Tim Vortherms*, Anne-Sophie Wesse, Arlene Manelli*, Andrew Swensen*,
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Grade Statistics without Bonus with Bonus Average = 86 Median = 87 Average = 88 Median = 89 Undergraduates Average=88 MS Average=92.
C LINICAL R ESEARCH. CONTENTS Drug Development Process Pre – Clinical Studies Clinical Trials Phase I Phase II Phase III Phase IV 2.
INTRODUCTION CLINICAL PHARMACOKINETICS
Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.
Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) M Shelton, S Ford, M Anderson, S Murray, J Ng-Cashin XVI.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical.
A Pharmacokinetic Drug Interaction Study of Drug-72 and Drug-12 Department of Mathematic & Statistics York University Yufeng Lin Xiaofeng Zhou.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
415 PHT Plasma Level – Time Curve
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
Robert A. Terkeltaub, Daniel E. Furst, Katherine Bennett, Karin A. Kook, R. S. Crockett, and Matthew W. Davis ARTHRITIS & RHEUMATISM Vol. 62, No. 4, April.
The process of drug development. Drug development 0,8 – 1 mld. USD.
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.
Dose Selection in Pharmaceutical Development Eliseo Salinas, MD, MSc Chief Scientific Officer Shire Pharmaceuticals.
PTI CF Subjects North American Cystic Fibrosis Conference October 27-29, 2016 Orlando, Florida CFTR amplifier is genotype agnostic with a distinct.
Drug Development Process Stages involved in Regulating Drugs
MONDAY-524 A Single-Centre, Double-Blind, Placebo-Controlled Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending.
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose.
The Stages of a Clinical Trial
Figure 1: Mean comparative midazolam plasma concentration-time plot
Eucrisa™ - Crisaborole
Drug Discovery &Development
Senior Medical Director, Cardiovascular
Evaluation of tolerability, pharmacokinetics, and anti-retroviral activity of MK-8591 in treatment-naïve HIV-1-infected adult subjects MK-8591 (EFdA)
Clinical Pharmacokinetics
Poster available online at:
Lanthanum pharmacokinetics: Are rat data misleading?
22nd International AIDS Conference (AIDS 2018)
Presentation transcript:

© Copyright 2015 Galapagos NV Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG1837 in healthy volunteers F.P. Vanhoutte 1, M-H. Gouy 2, F. Namour 2, W. Haazen 3, D. Kanters 1, G. De Beckker 1, K. Van de Wal 1, D. E. Geller 4 1 Galapagos NV, Generaal de Wittelaan L11 A3, 2800 Mechelen, Belgium 2 Galapagos SASU, 102 Avenue Gaston Roussel, Romainville, France 3 SGS-Clinical Pharmacology Unit, Lange Beeldekensstraat 267, 2060 Antwerp, Belgium 4 AbbVie, North Waukegan Road, North Chicago, IL 60064, US Introduction The restoration of CFTR channel activity with modulators targets the cause of CF disease. Galapagos has previously shown (NACFC 2013, ECFS 2014) the identification and development of a novel potentiator series with superior channel opening activity. The series was shown to have good metabolic stability and tissue permeability, supporting favorable pharmacokinetic characteristics in animals. From this series, GLPG1837 was selected to progress into formal pre-clinical and clinical studies as the first component of a CFTR-modulator combination. GLPG1837 has shown potent activity in cellular assays to improve the function of defective gating channels caused by specific CFTR mutations, with higher efficacy than ivacaftor. GLPG1837 can potentiate corrector-rescued Class II and Class III/IV CFTR defective channels. We speculate that this in vitro property will translate into an improved clinical benefit in CF patients. Following successful completion of formal preclinical safety evaluations, GLPG1837 was progressed to Phase 1 clinical evaluations in healthy volunteers. We here present results from these first clinical data. Methods Randomized, double-blind, placebo-controlled study over a range of single and multiple doses of GLPG1837 in healthy, adult subjects In the single ascending dose (SAD) part of the study, 2 alternating cohorts of subjects were exposed to single oral doses of 30 to 2000 mg in fasted conditions and to a single dose of 500mg after a high-fat high-calorie breakfast In the multiple ascending dose (MAD) part of the study, GLPG1837 was given orally at doses of 125 to 800 mg b.i.d. for a period of 14 days At every dose level 6 subjects were exposed to GLPG1837 and 2 to placebo Objectives Evaluate the safety and tolerability of single ascending doses (SAD), multiple ascending doses (MAD) of GLPG1837 compared to placebo. Determine the PK profile of GLPG1837 after single and twice daily dosing in healthy subjects; evaluate the impact of food on the bioavailability of GLPG1837 Conclusions Potentiator GLPG1837 was generally safe and well tolerated in healthy volunteers, with s ingle doses up to 2000 mg and 14-day dosing up to 800mg b.i.d. Final safety data analysis is pending, however preliminary data shows no SAE reported or concerning AEs GLPG1837 showed the following PK characteristics: Rapid absorption, and mean terminal half-life of 6-15 h after single doses. The exposure of GLPG1837 was approximately dose proportional at steady state Improved bioavailability with food Steady state was attained within 2 days of dosing, with no accumulation The metabolite also had high exposure (data not shown) These results support progression of GLPG1837 into a Phase 2 study in CF patients Poster available online at: NACFC 2015 Poster #258 Figure 1: Mean (±SE) GLPG1837 plasma concentrations after single oral dose as oral nanosuspension in fasted state; linear (top) and semi-logarithmic (bottom) plots. Single Ascending Dose Multiple Ascending Dose Figure 3: Mean (±SE) GLPG1837 plasma concentrations after multiple doses as oral nanosuspension Figure 4: dose normalised C max and AUC demonstrate steady state pharmacokinetics to be approximately dose proportional Improvement of exposure with food Figure 2: Mean (±SE) plasma concentrations after a 500 mg single dose as oral nanosuspension in fasted and fed state; linear (top) and semi- logarithmic (bottom) plots Preliminary Safety Results: GLPG1837 up to a single dose of 2000 mg and up to 800 mg b.i.d. for 14 days was generally safe and well tolerated. The assessment of blinded, unaudited safety data showed no SAEs or clinically relevant AEs, VS, ECG or lab changes. Number of subjects presenting with the event Dose group mg [Active or Pbo] fastedfed Blurred vision1 Tooth ache 1 Headache Common cold 1 Sore throat 1 Dizziness (orthostatic) 1 Vomiting 11 Diarrhea 1 Events with 2 or more occurrences of the event (# subjects) Dose group mg (b.i.d.) [Active or Pbo] Tiredness3 6 Headache4253 Nose congestion111 Nausea22 1 Dizziness1 3 Back pain1 11 Pharmacokinetic results Table 1: TEAE after single dose administrations Table 2: TEAE after multiple dose administrations for 14 days *AE results not yet MedDRA coded